Login / Signup
Efficacy of ALK inhibitors in Asian patients with ALK inhibitor-naïve advanced ALK -positive non-small cell lung cancer: a systematic review and network meta-analysis.
Xuchang Li
Yangchen Xia
Chengyan Wang
Shanshan Huang
Qian Chu
Published in:
Translational lung cancer research (2024)
-positive NSCLC. Iruplinalkib may have more favorable PFS benefit than other ALK inhibitors for Asians.
Keyphrases
</>
advanced non small cell lung cancer
epidermal growth factor receptor
small cell lung cancer